- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Renee Arnold Explains the Benefit of Pharmacoeconomic Analysis
With the high cost of medications, pharmacoeconomic analysis to determine the additional benefit being derived from additional cost is important, explained Renee JG Arnold, PharmD, RPh, practice lead for health economics and outcomes research at Quorum Consulting, Inc.
With the high cost of medications, pharmacoeconomic analysis to determine the additional benefit being derived from additional cost is important, explained Renee JG Arnold, PharmD, RPh, practice lead for health economics and outcomes research at Quorum Consulting, Inc
Transcript (slightly modified)
What is the importance of pharmacoeconomic analysis in healthcare decision making?
Well, pharmacoeconomic analysis is basically what somebody would consider cost effectiveness analysis. And it really helps to determine what is the additional benefit that you’re deriving for typically an additional cost, and especially with today’s pretty expensive medications it’s really important to determine if something is cost effective.
Can you provide an overview of the different types of evaluation techniques?
Right, so they really only differ in their denominator. Cost effectiveness or pharmacoeconomic analysis is basically cost divided by effectiveness. So if you do a cost minimization analysis you’re looking for equally effective agents or alternatives and, in which case, the denominator goes away basically. In a cost benefit analysis, the denominator is in monetary units so it’s dollars. Cost effectiveness analysis is usually some kind of metric like life years saved or myocardial infarction avoided. And cost utility analysis is a subgroup of cost effectiveness analysis in that it uses a quality of life adjustment to that effectiveness metric.
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Shaping Dermatology's Future by Increasing Access, Data, and Advocacy
March 7th 2025Thy N. Huynh, MD, FAAD, Bruce A. Brod, MHCI, MD, FAAD, and Melissa Piliang, MD, FAAD, discussed expanding access to pediatric dermatology, dermatology data aggregation, and advocacy for Medicare physician payment reform, respectively.
Read More
